The ability of human bispecific anti-idiotype antibody to elicit humoral and cellular immune responses in mice

International Immunopharmacology

Volumn 10, Issue 6, 2010, Pages 707-712

  Wang, Jia Jia ^a   Li, Yue Hui ^a   Liu, Yan Hong ^a   Song, Jie ^a   Guo, Feng Jie ^a   Li, Ya Lin ^a   Li, Guan Cheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Ab2 ; Bispecific antibody; Nasopharyngeal carcinoma

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTIIDIOTYPIC ANTIBODY VACCINE G22; ANTIIDIOTYPIC ANTIBODY VACCINE I50; BISPECIFIC ANTIIDIOTYPIC ANTIBODY VACCINE G22 I50; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNIZATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; FEMALE; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; ANTIBODIES, NEOPLASM; CANCER VACCINES; CARCINOMA; CELL PROLIFERATION; FEMALE; FREUND'S ADJUVANT; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; NASOPHARYNGEAL NEOPLASMS; SPLEEN;

EID: 77951878737     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.04.001     Document Type: Article

References (39)

1. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 1 (2006) 23
2. Schwegler C., Dorn-Beineke A., Nittka S., Stocking C., and Neumaier M. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice. Cancer Res 65 (2005) 1925-1933
3. Baral R., Sherrat A., Das R., Foon K.A., and Bhattacharya-Chatterjee M. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu. Int J Cancer 92 (2001) 88-95
4. Spendlove L., Li L., Potter V., Christiansen D., Loveland B.E., and Durrant L.G. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Eur J Immunol 30 (2000) 2944-2953
5. Uemura H., Beniers A.J., Okajima E., Debruyne F.M., and Oosterwijk E. Vaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity. Int J Cancer 58 (1994) 555-561
6. Di{dotless} ́az A., Alfonso M., Alonso R., Saurez G., Troche M., Catala M., et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107 (2003) 80-89
7. Birebent B., Mitchell E., Akis N., Li W.P., Somasundaram R., Purev E., et al. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine 21 (2003) 1601-1612
8. Foon K.A., Lutzky J., Baral R.N., Yannelli J.R., Hutchins L., Teitelbaum A., et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18 (2000) 376-384
9. Quan Jr. W.D., Dean G.E., Spears L., Spears C.P., Groshen S., Merritt J.A., et al. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. J Clin Oncol 15 (1997) 2103-2110
10. Samonigg H., Wilders-Truschnig M., Kuss I., Plot R., Stoger H., Schmid M., et al. A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J Immunother 22 (1999) 481-488
11. Zbar A.P., Thomas H., Wilkinson R.W., Wadhwa M., Syrigos K.N., Ross E.L., et al. Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study. Int J Colorectal Dis 20 (2005) 403-414
12. Chen S., Li B., Xie H., Xu L., Niu G., Fan K., et al. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma. Cancer Biother Radiopharm 19 (2004) 589-600
13. Otsuji E., Tsuruta H., Toma A., Kobayashi S., Okamoto K., Yata Y., et al. Effects of idiotypic human anti-mouse antibody against in vitro binding and antitumor activity of a monoclonal antibody-drug conjugate. Hepatogastroenterology 50 (2003) 380-384
14. Zhu H., Yang B., Yang X., Wang L., Xu J., Liao C., et al. A novel antibody fragment targeting HAb18G/CD147 with cytotoxicity and decreased immunogenicity. Cancer Biol Ther 8 (2009) 1035-1044
15. Presta L.G. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58 (2006) 640-656
16. Kreitman R., and Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: less than 1000 molecules per cell is sufficient for complete responses. Cancer Res 58 (1998) 968-975
17. Adams G.P., Schier R., Marshall K., Wolf E.J., McCall A.M., Marks J.D., et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58 (1998) 485-490
18. Desai S.A., Wang X., Noronha E.J., Kageshita T., and Ferrone S. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res 58 (1998) 2417-2425
19. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61 (2001) 4750-4755
20. Denton G., Brady K., Lo B.K., Murray A., Graves C.R., Hughes O.D., et al. Production and characterization of an anti-(MUC1 mucin) recombinant diabody. Cancer Immunol Immunother 48 (1999) 29-38
21. Santimaria M., Moscatelli G., Viale G.L., Giovannoni L., Neri G., Viti F., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 9 (2003) 571-579
22. Arndt M.A., Krauss J., and Rybak S.M. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers. FEBS Lett 578 (2004) 257-261
23. Robinson M.K., Doss M., Shaller C., Narayanan D., Marks J.D., Adler L.P., et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65 (2005) 1471-1478
24. He X., Li G., and Zhu J. Construction and selection of human anti-idiotypic antibody single chain variable fragments or CDR3 fragments of nasopharyngeal carcinoma. J Exp Clin Cancer Res 23 (2004) 607-615
25. He X.J., Li G.C., Zhu J.G., and Li Y.H. Construction of phage anti-idiotypic antibody library using sensitized in vitro B-lymphocytes of nasopharyngeal cancer patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19 (2003) 266-271
26. Li G.C., Zhu J.G., Zhou G.H., and Sun Q.B. Production of mono-clonal antibodies against nasopharyngeal cancer (NPC) by in vivo and vitro combining immunization. Hunan Med J 16 (1999) 326-328
27. Kunakorn M., Boonma P., Khupulsup K., and Petchclai B. Enzyme-linked immunosorbent assay for immunoglobulin M specific antibody for the diagnosis of melioidosis. J Clin Microbiol 28 (1990) 1249-1253
28. Wang S., Zhang C., Zhang L., Li J., Huang Z., and Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26 (2008) 2100-2110
29. Moreno A., Brocchi E., Lelli D., Gamba D., Tranquillo M., and Cordioli P. Monoclonal antibody based ELISA tests to detect antibodies against neuraminidase subtypes 1, 2 and 3 of avian influenza viruses in avian sera. Vaccine 27 (2009) 4967-4974
30. Ullenhag G.J., Spendlove I., Watson N.F., Kallmeyer C., Pritchard-Jones K., and Durrant L.G. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Immunol 128 (2008) 148-154
31. Maloney D.G., Grillo-López A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997) 2188-2195
32. Hernández A.M., Toledo D., Martínez D., Griñán T., Brito V., Macías A., et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 181 (2008) 6625-6634
33. Neninger E., Díaz R.M., de la Torre A., Rives R., Díaz A., Saurez G., et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 6 (2007) 145-150
34. Gordon A.N., Schultes B.C., Gallion H., Edwards R., Whiteside T.L., Cermak J.M., et al. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 94 (2004) 340-351
35. Pfisterer J., du Bois A., Sehouli J., Loibl S., Reinartz S., Reuss A., et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 17 (2006) 1568-1577
36. Yokota T., Milenic D.E., Whitlow M., and Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52 (1992) 3402-3408
37. Jerne N.K. Towards a network theory of the immune system. Ann Immunol 125 (1974) 373-389
38. Constant S.L., and Bottomly K. Induction of TH1 and TH2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15 (1997) 297-322
39. Schwegler C., Dorn-Beineke A., Nittka S., Stocking C., and Neumaier M. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice. Cancer Res 65 (2005) 1925-1933